- Austria / Österreich
- Bosnia and Herzegovina / Босна и Херцеговина
- Bulgaria / България
- Croatia / Hrvatska
- Czech Republic & Slovakia / Česká republika & Slovensko
- France / France
- Germany / Deutschland
- Greece / ΕΛΛΑΔΑ
- Italy / Italia
- Netherlands / Nederland
- Nordic / Nordic
- Poland / Polska
- Portugal / Portugal
- Romania & Moldova / România & Moldova
- Slovenia / Slovenija
- Serbia & Montenegro / Србија и Црна Гора
- Spain / España
- Switzerland / Schweiz
- Turkey / Türkiye
- UK & Ireland / UK & Ireland
JENA, Germany: Germany-based companies dentognostics and QIAGEN Lake Constance have recently entered into a partnership to enable use of the ImplantSafe test with the new QIAGEN aLF Reader diagnostic device. Aimed at identification of peri-implantitis, this combination detects subclinical inflammatory processes in their earliest stages by the quantitative assessment of the collagen-destroying enzyme aMMP-8 chairside directly on the patient.
“Dentognostics is excited to be bringing our ImplantSafe test, an aMMP8-based assay, to market exclusively with QIAGEN’s aLF Reader,” said Dirk-Rolf Gieselmann, Chairman of the Dentognostic Group.
Both companies believe the new method supplements clinical diagnosis such as the periodontal screening index and bleeding on probing (BOP) by identifying important immunological elements of subclinical collagen breakdown, which are not detectable in their early phase by radiography or probing. The sensitivity of the new method is between 75 and 95 per cent, up to three times more sensitive than BOP.
“QIAGEN is delighted to team with Dentognostics to bring its dental ImplantSafeDR immunoassay and our aLF lateral flow reader to dentists and their patients across the EU,” said Michael Doumanas, head of sales and marketing at QIAGEN Point-of-Need Systems.
With approximately 4 million affected implant patients in Germany alone, the sustainability of the replacement tooth could now be supported by an implant through the use of the dentognostics test in conjunction with QIAGEN’s reader.
“Together, the ImplantSafeDR test and aLF reader enable dentists to detect periimplantitis in its earliest stages to better protect dental implants. We look forward to continuing to work with Dentognostics to bring this important, new method to market, which will directly benefit dentists and their patients,” said Doumanas.
Interested parties can view the new technology at MEDICA 2017 from 13 to 16 November in Düsseldorf in Germany.
Tags:
Fri. 26 April 2024
12:00 pm EST (New York)
How you can access data-driven decision making
Mon. 29 April 2024
12:30 pm EST (New York)
Root caries: The challenge in today’s cariology
Tue. 30 April 2024
1:00 pm EST (New York)
Neodent Discovery: Neoarch Guided Surgery—from simple to complex cases
Fri. 3 May 2024
1:00 pm EST (New York)
Osseointegration in extrēmus: Complex maxillofacial reconstruction & rehabilitation praeteritum, praesens et futurum
Tue. 7 May 2024
8:00 pm EST (New York)
You got this! Diagnosis and management of common oral lesions
Thu. 9 May 2024
8:00 pm EST (New York)
Empowering your restorative practice: A comprehensive guide to clear aligner integration and success
Mon. 13 May 2024
9:00 am EST (New York)
To post a reply please login or register